Merck to pay up to $37M for VaxImmune license

Merck has licensed Coley Pharmaceutical's VaxImmune for $4 million up front and up to $33 million in milestones plus royalties. Merck gains the development rights to use VaxImmune in some vaccine programs for infectious diseases and Alzheimer's. VaxImmune is a proprietary Toll-like receptor 9 agonist designed to induce both an enhanced antigen-specific antibody response and a natural killer T-cell immune response when used in combination with prophylactic or therapeutic vaccines.

- read the release on the licensing deal

Suggested Articles

The clamor for more transparency from the leading pandemic vaccine contenders has been getting louder.

The role gives one of the driving forces behind Bristol Myers Squibb’s $74 billion takeover of Celgene the chance to help build biotechs.

The appointment gives Sino-American biotech Brii the experience of a man who helped Gilead launch eight drugs in China in quick succession.